Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

NCT05819138 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide affects heart health in adults with type 1 diabetes by measuring changes in the stiffness of the aorta.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 60 people Planned (estimated).

Who can join Ages 18–49 · all sexes

Timeline Started 2023-06 · est. completion 2027-12

Where 2 sites · United States

What this study is testing ClinicalTrials.gov NCT05819138 ↗

Description as written by the study sponsor.

This trial plans to learn more about the effects of a medication, semaglutide, on cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes. This medication has been effective in reducing cardiovascular disease and diabetic kidney disease and improving glucose control and BMI in adults with type 2 diabetes. This study aims to look at how well the medication works in people with type 1 diabetes. Semaglutide is not approved by the FDA to be used in this way. These procedures are considered to be experimental.

Treatments tested

Semaglutide Pen Injector also known as Ozempic Drug

Semaglutide injection
Placebo Drug

Semaglutide placebo injection

Main thing measured	Change in Ascending Aortic Pulse Wave Velocity (AA PWV)
Sponsor	University of Colorado, Denver
Conditions studied	Diabetes Mellitus, Type 1
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05819138 ↗